Osteoporosis 2016

Osteoporosis 2016 Year in Review – No new drug approvals, and a crisis in care

No new osteoporosis drugs hit the market this year, but two are progressing through the development pipeline and are showing promise. And while the efficacy and safety of denosumab (Prolia) have now been followed out to 10 years in a large clinical trial, the rate of use of bone-strengthening medica…
rheumnow.com

What’s new in Osteoporosis 2016: Odanacatib, Abaloparatide, Romosozumab

Amgen Highlights Enbrel, Prolia and Amjevita Research at ACR 2016

Amgen has released the presentation times and locations for 21 abstracts to be presented at the ACR/ARHP 2016 Annual Meeting in Washington next week.